Keyphrases
Relapsed or Refractory multiple Myeloma
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Clinical Evaluation
100%
Chimeric Antigen Receptor T-cell Therapy
100%
B-cell Maturation Antigen
100%
Clinical Determinants
100%
Confidence Interval
40%
Cell-to-cell
20%
Overall Survival
20%
Time Elapsed
20%
Multivariable
20%
Cellular Products
20%
Progression-free Survival
20%
Day Range
20%
Inclusion Criteria
20%
Complete Response
20%
Stringent Response
20%
Minimal Residual Disease
20%
Immune Effectors
20%
Light Chain Amyloidosis
20%
Median Progression-free Survival
20%
High-risk Cytogenetics
20%
Median Time
20%
Neurotoxicity Syndromes
20%
Hematotoxicity
20%
Organ Function
20%
Improved Patient Outcomes
20%
T Cell Delivery
20%
Extramedullary Disease
20%
Patient Enrollment
20%
Heavily Pretreated Patients
20%
Effector Memory T Cells
20%
Multiple Lights
20%
Cytokine Release Syndrome
20%
Performance Status
20%
Pivotal Trial
20%
Performance Baseline
20%
Medicine and Dentistry
Clinical Trial
100%
Multiple Myeloma
100%
Chimeric Antigen Receptor T-Cell
100%
B Cell Maturation Antigen
100%
Chimeric Antigen Receptor T-Cell Immunotherapy
100%
Disease
40%
Progression Free Survival
40%
Overall Survival
20%
Minimal Residual Disease
20%
Immunity
20%
Light Chain
20%
Amyloidosis
20%
Memory T Cell
20%
Cytokine Release Syndrome
20%
Toxicity and Intoxication
20%
Biochemistry, Genetics and Molecular Biology
T Cell
100%
Clinical Trial
100%
B Cell
100%
Cell Maturation
100%
Chimeric Antigen Receptor
100%
Progression Free Survival
28%
Cytogenetics
14%
Overall Survival
14%
Immunity
14%
Amyloidosis
14%
Light Chain
14%
Memory T Cell
14%
Cytokine Release Syndrome
14%
Immunology and Microbiology
Multiple Myeloma
100%
Chimeric Antigen Receptor T-Cell
100%
B Cell Maturation Antigen
100%
Chimeric Antigen Receptor T-Cell Therapy
100%
Progression Free Survival
40%
Overall Survival
20%
Memory T Cell
20%
Immunity
20%
Light Chain
20%
Amyloidosis
20%
Cytokine Release Syndrome
20%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Multiple Myeloma
100%
Chimeric Antigen Receptor
100%
B Cell Maturation Antigen
100%
Disease
28%
Progression Free Survival
28%
Overall Survival
14%
Minimal Residual Disease
14%
Amyloidosis
14%
Toxicity and Intoxication
14%
Cytokine Release Syndrome
14%